These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
Members of Outlawz have said for years that they mixed some of Tupac Shakur’s ashes…
State and local police made at least 218,152 marijuana-related arrests in 2025, including 200,960 for…
Three days in Philadelphia, September 25 to 27, with a free record-clearing clinic and a…
Four decades after its Amsterdam beginnings, Barney’s Farm is marking the milestone with new markets,…
Gallup’s new numbers hold a small, awkward pattern: the Americans most convinced cannabis is bad…
The FDA is seeking outside data and analytics services to better understand how people use…